These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33981617)

  • 1. Benefits and Limitations of TKIs in Patients with Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
    Efstathiadou ZA; Tsentidis C; Bargiota A; Daraki V; Kotsa K; Ntali G; Papanastasiou L; Tigas S; Toulis K; Pazaitou-Panayiotou K; Alevizaki M
    Eur Thyroid J; 2021 Apr; 10(2):125-139. PubMed ID: 33981617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.
    Klein Hesselink EN; Steenvoorden D; Kapiteijn E; Corssmit EP; van der Horst-Schrivers AN; Lefrandt JD; Links TP; Dekkers OM
    Eur J Endocrinol; 2015 May; 172(5):R215-25. PubMed ID: 25572389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 4. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
    Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
    Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
    Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
    Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
    Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
    Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis.
    Trimboli P; Castellana M; Virili C; Giorgino F; Giovanella L
    Front Endocrinol (Lausanne); 2018; 9():224. PubMed ID: 29774010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
    Massicotte MH; Brassard M; Claude-Desroches M; Borget I; Bonichon F; Giraudet AL; Do Cao C; Chougnet CN; Leboulleux S; Baudin E; Schlumberger M; de la Fouchardière C
    Eur J Endocrinol; 2014 Apr; 170(4):575-82. PubMed ID: 24424318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials.
    Yimaer W; Abudouyimu A; Tian Y; Magaoweiya S; Bagedati D; Wen H
    Onco Targets Ther; 2016; 9():1167-73. PubMed ID: 27022276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Tumor Activity and Safety of Multikinase Inhibitors in Advanced and/or Metastatic Thyroid Cancer: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Tsoli M; Alexandraki KI; Spei ME; Kaltsas GA; Daskalakis K
    Horm Metab Res; 2020 Jan; 52(1):25-31. PubMed ID: 31665790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib in progressive medullary thyroid cancer.
    Elisei R; Schlumberger MJ; Müller SP; Schöffski P; Brose MS; Shah MH; Licitra L; Jarzab B; Medvedev V; Kreissl MC; Niederle B; Cohen EE; Wirth LJ; Ali H; Hessel C; Yaron Y; Ball D; Nelkin B; Sherman SI
    J Clin Oncol; 2013 Oct; 31(29):3639-46. PubMed ID: 24002501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    Kocsis J; Szekanecz É; Bassam A; Uhlyarik A; Pápai Z; Rubovszky G; Mezősi E; Rucz K; Garai I; Nagy E; Uray I; Horváth Z
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):240-246. PubMed ID: 29506310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials.
    Wang H; Wang H; Yu Z; Liu H
    Onco Targets Ther; 2018; 11():5195-5201. PubMed ID: 30214225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Value of
    Werner RA; Schmid JS; Higuchi T; Javadi MS; Rowe SP; Märkl B; Aulmann C; Fassnacht M; Kroiss M; Reiners C; Buck AK; Kreissl MC; Lapa C
    J Nucl Med; 2018 May; 59(5):756-761. PubMed ID: 29025983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.